Shen Zhen, Ren Wanli, Bai Yanxia, Chen Zhengshuai, Li Jingjie, Li Bin, Jin Tianbo, Cao Peilong, Shao Yuan
Department of Otolaryngology & head neck, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
School of Life Sciences, Northwest University, Xi'an, Shaanxi 710069, China.
Oncotarget. 2016 Nov 29;7(48):79596-79604. doi: 10.18632/oncotarget.12865.
Laryngeal squamous cell carcinoma (LSCC) is one of the most common and aggressive malignancies of the upper digestive tract. The present study is a retrospective analysis of data from a prospective longitudinal study. A total of 170 male LSCC patients (average age, 60.75±10.082) at the First Affiliated Hospital of Xi'an Jiaotong University School of Medicine were recruited between January 2002 and April 2013 for this study. We assessed correlations between patient characteristics and survival, and sequenced genomic DNA from patient peripheral blood samples. We found that the single nucleotide polymorphisms (SNPs), rs11903757, with closest proximity to NABP1 and SDPR, and rs966423 in DIRC3, were associated with survival in LSCC patients. Median follow-up was 38 months (range 3-122) and median survival time was 48 months. LSCC patients with total laryngectomy, poor differentiation, T3-T4 stage, N1-N2 stage or III-IV TNM stage had reduced survival. This is the first study to demonstrate that the rs11903757 GT (HR=2.036; 95% CI, 1.071-3.872; p=0.030) and rs966423 TT (HR=11.677; 95% CI, 3.901-34.950; p=0.000) genotypes predict poor patient outcome. These polymorphisms may serve as useful clinical markers to predict patient survival, and to guide individual patient therapeutic decisions.
喉鳞状细胞癌（LSCC）是上消化道最常见且侵袭性最强的恶性肿瘤之一。本研究是一项对前瞻性纵向研究数据的回顾性分析。2002年1月至2013年4月期间，西安交通大学医学院第一附属医院共招募了170例男性LSCC患者（平均年龄60.75±10.082岁）参与本研究。我们评估了患者特征与生存率之间的相关性，并对患者外周血样本中的基因组DNA进行了测序。我们发现，与NABP1和SDPR距离最近的单核苷酸多态性（SNP）rs11903757以及DIRC3中的rs966423与LSCC患者的生存率相关。中位随访时间为38个月（范围3 - 122个月），中位生存时间为48个月。接受全喉切除术、分化差、T3 - T4期、N1 - N2期或III - IV期TNM分期的LSCC患者生存率降低。这是第一项证明rs11903757 GT（HR = 2.036；95% CI，1.071 - 3.872；p = 0.030）和rs966423 TT（HR = 11.677；95% CI，3.901 - 34.950；p = 0.000）基因型可预测患者不良预后的研究。这些多态性可能作为有用的临床标志物来预测患者生存率，并指导个体化患者的治疗决策。
